News Releases

Keyword Search
 
DateTitle  
10/13/17Dermira Highlights New Long-Term Safety Data for Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis at Fall Clinical Dermatology Conference
- Daily treatment with glycopyrronium tosylate in the Phase 3, open-label ARIDO trial was generally well-tolerated during 44 weeks of treatment - Efficacy assessment suggests sweat reduction levels were maintained in patients treated with glycopyrronium tosylate during the extended study MENLO PARK, Calif., Oct. 13, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, ne... 
 Printer Friendly Version
10/05/17Dermira Completes Patient Enrollment in Two Phase 3 Pivotal Trials of Olumacostat Glasaretil for the Treatment of Acne Vulgaris
- Phase 3 pivotal trials enrolled a total of 1,503 patients - Topline efficacy and safety results expected in first quarter of 2018 MENLO PARK, Calif., Oct. 05, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced the completion of patient enrollment in its CLAREOS-1 and CLAREOS... 
 Printer Friendly Version
09/20/17Dermira to Present at Cantor Fitzgerald Global Healthcare Conference
MENLO PARK, Calif., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that it will present at the Cantor Fitzgerald 2017 Global Healthcare Conference. Andrew Guggenhime, chief operating officer and chief financial officer of Dermira, is scheduled to present at 8:00 a.... 
 Printer Friendly Version
09/14/17Dermira Announces Early Termination of the Hart-Scott-Rodino Waiting Period for License to Lebrikizumab
MENLO PARK, Calif., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that it has received early termination of the waiting period required by the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR), related to its license to lebrikizumab.  The e... 
 Printer Friendly Version
09/14/17New CIMZIA® (certolizumab pegol) Findings Presented at European Academy of Dermatology and Venereology (EADV) Congress
Presentations included the first 48-week data from the CIMPASI-1 and CIMPASI-2 psoriasis trials, and re-randomized data through 48 weeks from the CIMPACT psoriasis trial 1,2 Treatment with CIMZIA was associated with significant and clinically meaningful improvements in quality of life and work productivity 3,4 No new safety signals were observed in the psoriasis trials and the safety profile remains consistent with CIMZIA’s other indications Additional presentations highlighted findings... 
 Printer Friendly Version
09/13/17Dermira Presents New Data Showing Impact of Primary Axillary Hyperhidrosis on Patients
People suffering from primary axillary hyperhidrosis (excessive underarm sweating beyond what is needed to maintain normal body temperature) report that the condition has a significant impact on their daily lives, often resulting in avoidance of social interactions and taking additional measures to manage their excessive sweating  Patients treated with glycopyrronium tosylate in Phase 3 clinical trials reported greater improvements across several measures designed to evaluate the impact of th... 
 Printer Friendly Version
09/07/17Dermira Presents New Data on Late-Stage Programs at Leading European Dermatology Congress
New findings from the glycopyrronium tosylate Phase 3 program highlight potential benefits of the investigational treatment and the impact of primary axillary hyperhidrosis on patients’ daily activities In collaboration with UCB, new 48-week data and quality of life findings from three clinical trials evaluating CIMZIA® (certolizumab pegol) in patients with moderate-to-severe chronic plaque psoriasis will also be presented MENLO PARK, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Dermira,... 
 Printer Friendly Version
08/08/17Dermira Enters into Agreement to License Exclusive, Worldwide Rights to Lebrikizumab
-  Dermira plans to develop and commercialize lebrikizumab, a monoclonal antibody targeting IL-13, for moderate-to-severe atopic dermatitis -  Initiation of a Phase 2b clinical study is expected in the first quarter of 2018 -  Management will host webcast and conference call today at 5:30 a.m. PT / 8:30 a.m. ET MENLO PARK, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by de... 
 Printer Friendly Version
08/07/17Dermira Reports Second Quarter 2017 Financial Results and Provides Corporate Update 
sBLA for CIMZIA® (certolizumab pegol) submitted to FDA Submission of NDA for glycopyrronium tosylate on schedule for second half of 2017 Guidance for Phase 3 olumacostat glasaretil topline results updated to first quarter of 2018 MENLO PARK, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with c... 
 Printer Friendly Version
07/25/17UCB and Dermira Announce U.S. and EU Regulatory Submissions for CIMZIA® (certolizumab pegol) for the treatment of Moderate-to-Severe Chronic Plaque Psoriasis
The regulatory submissions for this new indication seek to expand the use of CIMZIA for the treatment of patients with moderate-to-severe chronic plaque psoriasis Data from three positive Phase 3 studies support the regulatory submissions BRUSSELS, Belgium and MENLO PARK, Calif., July 25, 2017 (GLOBE NEWSWIRE) -- UCB (Euronext:UCB) and Dermira, Inc. (NASDAQ:DERM) today announced the UCB submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administ... 
 Printer Friendly Version
06/26/17Newly Published Nonclinical Data Highlight the Role of Olumacostat Glasaretil in Sebum Inhibition
MENLO PARK, Calif., June 26, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that findings from nonclinical studies evaluating the mechanism of action for olumacostat glasaretil (formerly DRM01) in sebum inhibition were published in the Journal of Investigative Dermatology (J... 
 Printer Friendly Version
06/06/17Dermira Announces Appointment of Ian Clements as Vice President, Investor Relations
MENLO PARK, Calif., June 06, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, announced today the addition of Ian Clements, Ph.D., to the company's leadership team as vice president, investor relations. Dr. Clements brings over 20 years of industry experience to Dermira. Most recently, he ... 
 Printer Friendly Version
05/30/17Dermira to Present at Jefferies 2017 Global Healthcare Conference
MENLO PARK, Calif., May 30, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that it will present at the Jefferies 2017 Global Healthcare Conference. Andrew Guggenhime, chief operating officer and chief financial officer of Dermira, is scheduled to present at 11:00 a.m. ET (8:... 
 Printer Friendly Version
05/16/17Dermira Announces Closing of 3.00% Convertible Senior Notes Offering
MENLO PARK, Calif., May 16, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM) announced today the closing of its previously announced offering of 3.00% Convertible Senior Notes due 2022 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Dermira issued $287.5 million aggregate principal amount of notes, including $37.5 million aggregate principal amount of notes issued pursuant to t... 
 Printer Friendly Version
05/10/17Dermira Prices Offering of $250 Million of 3.00% Convertible Senior Notes
MENLO PARK, Calif., May 10, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM) announced today the pricing of its offering of $250,000,000 aggregate principal amount of 3.00% Convertible Senior Notes due 2022 (the “notes”) in a private offering to qualified institutional buyers pursuant to the Securities Act of 1933, as amended (the “Securities Act”). Dermira also granted the initial purchasers of the notes a 30-day over-allotment option to purchase up to an additional $37,500,000 aggregate ... 
 Printer Friendly Version
05/09/17Dermira Announces Proposed Offering of $250 Million of Convertible Senior Notes
MENLO PARK, Calif., May 09, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM) announced today that it intends to offer, subject to market conditions and other factors, $250,000,000 aggregate principal amount of Convertible Senior Notes due 2022 (the “notes”) in a private offering to qualified institutional buyers pursuant to the Securities Act of 1933, as amended (the “Securities Act”). Dermira also intends to grant the initial purchasers of the notes a 30-day over-allotment option to purch... 
 Printer Friendly Version
05/08/17Dermira Reports First Quarter 2017 Financial Results and Provides Corporate Update 
-Submissions for CIMZIA® (certolizumab pegol) and glycopyrronium tosylate remain on schedule for later this year MENLO PARK, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today reported financial results for the quarter ended March 31, 2017 and provided an update on its cl... 
 Printer Friendly Version
03/28/17Dermira to Present at Needham 16th Annual Healthcare Conference
MENLO PARK, Calif., March 28, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that it will present at the Needham & Company 16th Annual Healthcare Conference. Andrew Guggenhime, chief operating officer and chief financial officer of Dermira, is scheduled to present at 2:2... 
 Printer Friendly Version
03/21/17Dermira Presents New Data Highlighting Patient Outcomes in Axillary Hyperhidrosis at Maui Derm Meeting
Proprietary Axillary Sweating Daily Diary patient-reported outcome instrument developed with feedback from FDA MENLO PARK, Calif., March 21, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today presented new information about the Axillary Sweating Daily Diary (ASDD), a proprietary patient-... 
 Printer Friendly Version
03/17/17Dermira to Highlight Data for Three Clinical Programs at Annual Maui Derm Meeting
New data for the Axillary Sweating Daily Diary patient-reported outcome instrument from the glycopyrronium tosylate Phase 2 trial in primary axillary hyperhidrosis to be highlighted Additional data from the CIMPACT Phase 3 trial of CIMZIA® (certolizumab pegol) in patients with moderate-to-severe psoriasis will be presented MENLO PARK, Calif., March 17, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical der... 
 Printer Friendly Version
03/07/17Dermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
MENLO PARK, Calif., March 07, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that it has closed its previously announced public offering of 5,750,000 shares of its common stock, including 750,000 shares sold upon full exercise of the underwriters’ option to purchase addition... 
 Printer Friendly Version
03/04/17New CIMZIA® (certolizumab pegol) data in moderate-to-severe plaque psoriasis and psoriatic arthritis presented at American Academy of Dermatology 2017 Annual Meeting
Late-breaking, investigational 16-week data presented from the CIMPASI-1 and CIMPASI-2 trials showing CIMZIA demonstrated statistically and clinically significant improvements for patients with moderate-to-severe chronic plaque psoriasis Four-year data from the CIMZIA RAPID-PSA study showing long-term maintenance of improvement in the joint and skin manifestations of psoriatic arthritis regardless of prior exposure to an anti-TNF, or as monotherapy without concomitant use of disease modifyi... 
 Printer Friendly Version
03/03/17Dermira Presents New Data in Primary Axillary Hyperhidrosis and Acne at American Academy of Dermatology 2017 Annual Meeting
Data from glycopyrronium tosylate Phase 3 program and olumacostat glasaretil Phase 2 trial show patients experienced early and sustained clinical effects with each treatment ORLANDO, Fla., March 03, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced new data, from its glycopyrr... 
 Printer Friendly Version
03/02/17Dermira to Present at Cowen and Company 37th Annual Health Care Conference
MENLO PARK, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that it will present at the Cowen and Company 37th Annual Health Care Conference. Tom Wiggans, chairman and chief executive officer of Dermira, is scheduled to present at 4:00 p.m. ET (1:00 p.m. PT)... 
 Printer Friendly Version
03/01/17Dermira Prices $168.5 Million Public Offering of Common Stock
MENLO PARK, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced the pricing of its underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $33.70 per share. The gross proceeds to Dermira from the offering, before deductin... 
 Printer Friendly Version
02/28/17Dermira Announces Proposed Public Offering of Common Stock
MENLO PARK, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that it intends to offer 3,700,000 shares of its common stock in an underwritten public offering. Dermira also expects to grant to the underwriters a 30-day option to purchase up to 555,000 additiona... 
 Printer Friendly Version
02/28/17Dermira Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
-- Planned submission of NDA for glycopyrronium tosylate (formerly DRM04) in 2H17 on schedule after pre-NDA meeting with FDA -- -- Management to host webcast and conference call today 4:30 p.m. ET / 1:30 p.m. PT -- MENLO PARK, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions... 
 Printer Friendly Version
02/27/17Dermira Data from DRM04 and Olumacostat Glasaretil Clinical Programs to Be Presented at American Academy of Dermatology Annual Meeting
MENLO PARK, Calif., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that data from its DRM04 and olumacostat glasaretil (formerly DRM01) clinical programs will be presented during poster sessions at the 75th Annual Meeting of the American Academy of Dermatology (AAD) being held in Or... 
 Printer Friendly Version
02/22/17Dermira to Report Fourth Quarter and Full Year 2016 Financial Results
Management to Host Webcast and Conference Call on February 28, 2017 at 4:30 p.m. ET MENLO PARK, Calif., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that it will report fourth quarter and full year 2016 financial results after the close of U.S. financial markets on February 28, 2... 
 Printer Friendly Version
02/08/17Dermira to Present at Leerink Partners 6th Annual Global Healthcare Conference
MENLO PARK, Calif., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. DERM, a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that it will present at the Leerink Partners 6th Annual Global Healthcare Conference. Tom Wiggans, chairman and chief executive officer of Dermira, is scheduled to present at 1:30 p.m. ET (10:30 a.m. PT) on Wednesday, February ... 
 Printer Friendly Version
01/19/17Final CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Primary Efficacy Endpoint in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
CIMPACT results confirm data from two previously reported Phase 3 CIMZIA trials Submission of marketing applications to regulatory authorities expected in third quarter of 2017 BRUSSELS, Belgium and MENLO PARK, Calif., Jan. 19, 2017 (GLOBE NEWSWIRE) -- UCB (Euronext:UCB) and Dermira, Inc. (NASDAQ:DERM) today announced key results from CIMPACT, a Phase 3, multi-center, placebo-controlled and active-controlled clinical trial evaluating the efficacy and safety of CIMZIA® (certolizumab pe... 
 Printer Friendly Version
01/06/17Dermira Provides Corporate Update
Treatment period for DRM04 ARIDO trial completed Phase 3 acne clinical program for olumacostat glasaretil initiated Topline data for third and final CIMZIA® (certolizumab pegol) Phase 3 trial expected first quarter of 2017 Chief Commercial Officer appointed MENLO PARK, Calif., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of... 
 Printer Friendly Version
01/05/17Lori Lyons-Williams Joins Dermira as Chief Commercial Officer
Previously served at Allergan as a Vice President for Sales & Marketing, member of Operational Leadership Team Worked on several leading dermatology brands including ACZONE® and BOTOX® during 15-year career at Allergan MENLO PARK, Calif., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, t... 
 Printer Friendly Version
01/04/17Dermira Elects Emmanuel Caeymaex to Board of Directors
Currently Executive Vice President, Immunology Patient Value Unit Head at UCB S.A. MENLO PARK, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced the election of Emmanuel Caeymaex, Executive Vice President, Immunology Patient Value Unit Head at UCB S.A., to its board of directo... 
 Printer Friendly Version
01/03/17Dermira Initiates Phase 3 Clinical Program in Acne
First patients dosed in Phase 3 program evaluating olumacostat glasaretil, a novel topical molecule, in patients with acne vulgaris Two Phase 3 trials expected to enroll a total of 1,400 patients Topline results expected in the first half of 2018 MENLO PARK, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with... 
 Printer Friendly Version
12/08/16Second CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Co-primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
Topline results from CIMPASI-1, the second of three Phase 3 trials in psoriasis clinical development program Findings confirm CIMZIA results observed in earlier CIMPASI-2 trial Results from third and final Phase 3 trial expected 1Q17 BRUSSELS, Belgium and MENLO PARK, Calif., Dec. 08, 2016 (GLOBE NEWSWIRE) -- UCB (Euronext:UCB) and Dermira, Inc. (NASDAQ:DERM) today announced topline results from CIMPASI-1, a Phase 3, multi-center, placebo-controlled clinical trial evaluating the effica... 
 Printer Friendly Version
11/09/16Dermira to Present at Stifel 2016 Healthcare Conference
MENLO PARK, Calif., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that it will present at the Stifel 2016 Healthcare Conference. Tom Wiggans, chairman and chief executive officer of Dermira, is scheduled to present at 11:00 a.m. ET (8:00 a.m. PT) on Wednesday, November 16, 2016, in... 
 Printer Friendly Version
11/07/16Dermira Reports Third Quarter 2016 Financial Results and Provides Corporate Update
- Topline results for the first of three Phase 3 trials for CIMZIA® reported - DRM04 Phase 3 and DRM01 Phase 2b data presented at dermatology conferences - Acquired option to license rights to early-stage programs from Takeda - Licensed DRM04 for hyperhidrosis to Maruho in Japan MENLO PARK, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to impr... 
 Printer Friendly Version
10/21/16Dermira Presents Data from DRM01 Phase 2b Clinical Program at Annual Meeting for Dermatologists
MENLO PARK, Calif., Oct. 21, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, presented data from its DRM01 Phase 2b clinical trial at the 35th Anniversary Fall Clinical Dermatology Conference in Las Vegas. Positive topline results from the DRM01 Phase 2b dose-ranging clinical trial were previously reporte... 
 Printer Friendly Version
10/13/16Dermira to Present Data from DRM01 and DRM04 Clinical Programs at Fall Clinical Dermatology Conference
MENLO PARK, Calif., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that data from its DRM01 and DRM04 clinical programs will be presented at the 35th Anniversary Fall Clinical Dermatology Conference being held in Las Vegas Oct. 20 – 23, 2016. Updated data regarding dose efficacy ... 
 Printer Friendly Version
10/03/16CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Co-primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
Topline results from the first of three Phase 3 trials in psoriasis clinical development program BRUSSELS, Belgium and MENLO PARK, Calif., Oct. 03, 2016 (GLOBE NEWSWIRE) -- UCB (Euronext:UCB) and Dermira, Inc. (NASDAQ:DERM) today announced topline results from CIMPASI-2, a Phase 3, multi-center, placebo-controlled clinical trial evaluating the efficacy and safety of CIMZIA® (certolizumab pegol) in adult patients with moderate-to-severe chronic plaque psoriasis. In the CIMPASI-2 trial, CIMZIA ... 
 Printer Friendly Version
10/01/16Dermira Presents Data from DRM04 Phase 3 Clinical Program in Late-Breaking News Session at European Academy of Dermatology and Venereology Congress
MENLO PARK, Calif., Oct. 01, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today presented data, including new disease-related quality of life data, from its DRM04 Phase 3 clinical program in patients with primary axillary hyperhidrosis (excessive underarm sweating) in a late-breaking news session at the 2... 
 Printer Friendly Version
09/28/16Dermira to Present Data from DRM04 Phase 3 Clinical Trials at Late-Breaking News Session at European Academy of Dermatology and Venereology Congress
MENLO PARK, Calif., Sept. 28, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that data from its DRM04 Phase 3 clinical program in patients with primary axillary hyperhidrosis (excessive underarm sweating) will be presented in a late-breaking news session at the 25th European Academy of Derma... 
 Printer Friendly Version
09/20/16Dermira Licenses DRM04 to Maruho for Hyperhidrosis in Japan
Terms include $25 million upfront license payment to Dermira Maruho to fund all development and commercial costs for DRM04 in Japan MENLO PARK, Calif., Sept. 20, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced it has entered into an exclusive license agreement with Maruho Co., Ltd., a... 
 Printer Friendly Version
09/12/16Dermira Acquires Option to License Exclusive Rights for up to Three Early-Stage Programs from Takeda
MENLO PARK, Calif., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that it has entered into an exclusive option and license agreement with Takeda Pharmaceutical Company Limited (TSE: 4502). Pursuant to the terms of the agreement, Dermira has acquired an option to license exclusive ... 
 Printer Friendly Version
08/08/16Dermira Reports Second Quarter 2016 Financial Results and Provides Corporate Update
Reported Topline Results for Two Late-Stage Clinical Programs Raised Approximately $136 Million in Net Proceeds from Follow-on Public Offering Updates Guidance for Topline Phase 3 CIMZIA® (certolizumab pegol) Clinical Program Results MENLO PARK, Calif., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermat... 
 Printer Friendly Version
06/13/16Dermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
MENLO PARK, Calif., June 13, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that it has closed its previously announced public offering of 5,175,000 shares of its common stock, including 675,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares of commo... 
 Printer Friendly Version
06/08/16Dermira Prices $126 Million Public Offering of Common Stock
MENLO PARK, Calif., June 08, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced the pricing of its underwritten public offering of 4,500,000 shares of its common stock at a price to the public of $28.00 per share. The gross proceeds to Dermira from the offering, before deducting the underwriting... 
 Printer Friendly Version
06/07/16Dermira Announces Proposed Public Offering of Common Stock
MENLO PARK, Calif., June 07, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that it intends to offer shares of its common stock in an underwritten public offering. Dermira also expects to grant to the underwriters a 30-day option to purchase additional shares of its common stock in an amount... 
 Printer Friendly Version
06/01/16Dermira Announces Positive Topline Results from Two Pivotal Phase 3 Clinical Trials for DRM04 in Patients with Primary Axillary Hyperhidrosis
Management to Host Webcast and Conference Call Today at 1:30 p.m. PT / 4:30 p.m. ET MENLO PARK, Calif., June 01, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced topline results from its Phase 3 ATMOS-1 and ATMOS-2 pivotal trials for DRM04, a topical anticholinergic product candidate in devel... 
 Printer Friendly Version
05/11/16Dermira to Present Preclinical Data from DRM01 Acne Program at the Society for Investigative Dermatology 75th Annual Meeting
MENLO PARK, Calif., May 11, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that preclinical data for the DRM01 acne program will be presented in an oral presentation during the Society for Investigative Dermatology 75th Annual Meeting (SID), May 11-14, in Scottsdale, Arizona. The results of ... 
 Printer Friendly Version
05/10/16Dermira Reports First Quarter 2016 Financial Results and Provides Corporate Update
- Positive Topline Results for DRM01 Phase 2b Acne Trial Reported; Phase 3 Program Planning Underway - Announcement of Topline Results for DRM04 Phase 3 Hyperhidrosis Pivotal Trials Expected in Second Quarter of 2016 MENLO PARK, Calif., May 10, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today repo... 
 Printer Friendly Version
05/10/16Dermira Announces Positive Topline Phase 2b Clinical Trial Results for DRM01 in Patients with Facial Acne Vulgaris
- Safety and Efficacy Data Confirm Results from Previous Phase 2a Trial - DRM01 Phase 3 Clinical Program Planning Underway - Management to Host Webcast and Conference Call Today at 5:30 a.m. PT / 8:30 a.m. ET MENLO PARK, Calif., May 10, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced topli... 
 Printer Friendly Version
04/05/16Dermira to Present at 15th Annual Needham Healthcare Conference
MENLO PARK, Calif., April 05, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced participation in the 15th Annual Needham Healthcare Conference. Tom Wiggans, chairman and chief executive officer of Dermira, is scheduled to present at 12:50 p.m. ET (9:50 a.m. PT) on Tuesday, April 12, 2016, in Ne... 
 Printer Friendly Version
03/14/16Dermira’s Co-founder and Chief Medical Officer, Eugene A. Bauer, M.D., Receives Presidential Citation from the American Academy of Dermatology
MENLO PARK, Calif., March 14, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that Eugene A. Bauer, M.D., co-founder and chief medical officer of Dermira, has received a Presidential Citation from the American Academy of Dermatology (AAD). Dr. Bauer received the award at the Stars of the Acad... 
 Printer Friendly Version
03/03/16Dermira Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
Management to Host Webcast and Conference Call Today at 5:30 a.m. PT / 8:30 a.m. ET MENLO PARK, Calif., March 03, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today reported financial results for the quarter and year ended December 31, 2015 and provided an update on its clinical development programs and ... 
 Printer Friendly Version
03/01/16Dermira to Report Fourth Quarter and Full Year 2015 Financial Results
Management to Host Webcast and Conference Call on March 3, 2016 at 8:30 a.m. ET MENLO PARK, Calif., March 01, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that it will report fourth quarter and full year 2015 financial results before the open of U.S. financial markets on March 3, 2016. De... 
 Printer Friendly Version
03/01/16Dermira to Present at Cowen and Company 36th Annual Health Care Conference
MENLO PARK, Calif., March 01, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that it will present at the Cowen and Company 36th Annual Health Care Conference. Tom Wiggans, chairman and chief executive officer of Dermira, is scheduled to present at 8:40 a.m. ET on Tuesday, March 8, 2016, in B... 
 Printer Friendly Version
02/29/16Dermira Completes Patient Enrollment for DRM04 Phase 3 Pivotal Trials in Primary Axillary Hyperhidrosis
Topline Results for Phase 3 ATMOS-1 and ATMOS-2 Clinical Trials Expected in 2Q 2016 MENLO PARK, Calif., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced the completion of patient enrollment in its Phase 3 ATMOS-1 and ATMOS-2 clinical trials for DRM04 in primary axillary hyperhidrosis... 
 Printer Friendly Version
02/04/16Dermira to Present at the Leerink Partners 5th Annual Global Healthcare Conference
MENLO PARK, Calif., Feb. 04, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that it will present at the Leerink Partners 5th Annual Global Healthcare Conference. Tom Wiggans, chairman and chief executive officer of Dermira, is scheduled to present at 11:35 a.m. ET on Thursday, February 11, 2... 
 Printer Friendly Version
01/08/16Dermira Completes Patient Enrollment for Third CIMZIA® (certolizumab pegol) Phase 3 Clinical Trial in Psoriasis Program and Updates Guidance for Release of Topline Data
Enrollment for All Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Plaque Psoriasis Completed Dermira Plans to Announce Topline Data for Phase 3 Trials by End of First Quarter 2017   MENLO PARK, Calif., Jan. 08, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced the complet... 
 Printer Friendly Version
01/07/16Dermira Provides DRM01 and DRM04 Development Program Updates
Enrollment Completed in DRM01 Phase 2b Acne Trial; Topline Data Expected in 2Q16 Topline Data for DRM04 Phase 3 Hyperhidrosis Program Expected Mid-2016 MENLO PARK, Calif., Jan. 07, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced an update for its DRM01 and DRM04 development programs. Pa... 
 Printer Friendly Version
12/15/15Dermira Added to NASDAQ Biotechnology Index
MENLO PARK, Calif., Dec. 15, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced that the company has been selected for addition to the NASDAQ Biotechnology Index® (NBI) as of December 21, 2015. The NBI is designed to track the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or pharmaceutical acc... 
 Printer Friendly Version
11/19/15Dermira Completes Patient Enrollment for Second CIMZIA(R) (certolizumab pegol) Phase 3 Clinical Trial in Psoriasis Program
Enrollment Continues for Third and Final CIMZIA Phase 3 Trial in Patients With Moderate-to-Severe Plaque Psoriasis MENLO PARK, Calif., Nov. 19, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced the completion of patient enrollment for the global CIMPASI-1 clinical trial of CIMZIA® (certolizumab pegol) in adult patients with moderate-to-severe... 
 Printer Friendly Version
11/10/15Dermira Reports Third Quarter 2015 Financial Results and Provides Corporate Update
Continued Progress for Three Late-Stage Development Programs MENLO PARK, Calif., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today reported financial results for the quarter ended September 30, 2015 and provided an update on its clinical development programs. "Our clinical development programs continue to move forward, and I am pleased to ... 
 Printer Friendly Version
10/12/15Dermira Completes Patient Enrollment for First CIMZIA(R) (Certolizumab Pegol) Phase 3 Clinical Trial in Psoriasis Program
Patient Enrollment Continues for Two Additional CIMZIA Phase 3 Trials in Patients With Moderate-to-Severe Psoriasis MENLO PARK, Calif., Oct. 12, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced the completion of patient enrollment for the global CIMPASI-2 clinical trial of CIMZIA® (certolizumab pegol) in adult patients with moderate-to-sever... 
 Printer Friendly Version
10/07/15Dermira Presents Data From DRM01 Phase 2a Trial at European Academy of Dermatology and Venereology
Includes New Data Regarding Effects Observed at Week 4 MENLO PARK, Calif., Oct. 7, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced the presentation of data for DRM01, a novel, topical sebum inhibitor in development for the treatment of acne. Topline data from the company's Phase 2a study showed that DRM01 met all of the primary efficacy end... 
 Printer Friendly Version
09/30/15Dermira Elects Kathleen Sebelius to Board of Directors
MENLO PARK, Calif., Sept. 30, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced the election of Kathleen Sebelius, the 21st U.S. Secretary of Health and Human Services, to its board of directors. "We are honored and excited to welcome Kathleen Sebelius to Dermira's board of directors," said Tom Wiggans, chairman and chief executive officer... 
 Printer Friendly Version
09/29/15Dermira to Present Data for DRM01 Acne Program at EADV Congress 2015
Additional Analyses of Phase 2a Study to Be Presented on October 7, 2015 MENLO PARK, Calif., Sept. 29, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced that new data from its DRM01 acne program will be presented at the European Academy of Dermatology and Venereology (EADV) Congress 2015 being held October 7-11, 2015 in Copenhagen. The de... 
 Printer Friendly Version
09/10/15Skin Disposition Study Results for Dermira's DRM01 Program in Acne Presented at International Dermatology Meeting
Animal Data Demonstrate Accumulation of DRM01 in Sebaceous Glands Following Topical Administration MENLO PARK, Calif., Sept. 10, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced the presentation of new data for DRM01, a novel, topical sebum inhibitor in development for the treatment of acne. The results from a study in Yorkshire pigs demonst... 
 Printer Friendly Version
09/03/15Dermira to Present Data for DRM01 Acne Program at 45th Annual ESDR Meeting
Results of Skin Disposition Study to be Presented on September 10, 2015 MENLO PARK, Calif., Sept. 3, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced that data from its DRM01 acne program will be presented at the 45th Annual Meeting of the European Society for Dermatological Research (ESDR) being held September 9-12, 2015 in Rotterdam, Nethe... 
 Printer Friendly Version
08/13/15Dermira Reports Second Quarter 2015 Financial Results and Provides Corporate Update
Two Product Candidates Now in Phase 3 Development Approximately $104 Million in Net Proceeds From Recent Follow-on Public Offering MENLO PARK, Calif., Aug. 13, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today reported financial results for the quarter ended June 30, 2015 and provided an update on its clinical development programs. "I am ver... 
 Printer Friendly Version
08/11/15Dermira Announces Closing of Follow-on Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
MENLO PARK, Calif., Aug. 11, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced that it has closed its previously announced follow-on public offering of 5,175,000 shares of its common stock, including 675,000 shares sold upon full exercise of the underwriters' option to purchase additional shares of common stock, at a price to the public of $21... 
 Printer Friendly Version
08/05/15Dermira Prices Follow-On Public Offering of Common Stock
MENLO PARK, Calif., Aug. 5, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced the pricing of its follow-on public offering of 4,500,000 shares of its common stock at a price to the public of $21.50 per share. In addition, Dermira has granted the underwriters a 30-day option to purchase up to an additional 675,000 shares of its common stock, on... 
 Printer Friendly Version
08/04/15Dermira Commences Follow-on Public Offering of Common Stock
MENLO PARK, Calif., Aug. 4, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced that it has commenced a follow-on public offering of 3,750,000 shares of its common stock. Dermira also intends to grant to the underwriters a 30-day option to purchase up to an additional 562,500 shares of its common stock, on the same terms and conditions. The offe... 
 Printer Friendly Version
08/03/15Dermira Doses First Patients in DRM04 Phase 3 Program in Axillary Hyperhidrosis
Two Identical Studies to Enroll a Combined Total of 660 Patients Topline Phase 3 Data Expected in the Second Half of 2016 Represents Dermira's Second Product Candidate in Phase 3 Development Dermira Updates 2015 Financial Guidance MENLO PARK, Calif., Aug. 3, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced the initial dosing ... 
 Printer Friendly Version
06/09/15Dermira's Phase 2a DRM01 Acne Trial Data Presented at the World Congress of Dermatology Meeting
Primary Endpoints of Changes in Lesion Counts and Improvement in Investigator's Global Assessment (IGA) Score Met With Statistical Significance MENLO PARK, Calif., June 9, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced the presentation of clinical data from its successful DRM01 Phase 2a trial in patients with acne vulgaris. A poster presen... 
 Printer Friendly Version
06/02/15Dermira Announces Poster Presentation on DRM01 in Acne at World Congress of Dermatology
Safety and Efficacy Results of Phase 2a Trial to be Displayed June 9-12, 2015 MENLO PARK, Calif., June 2, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced that clinical data from its DRM01 Phase 2a trial in acne will be presented at the 23rd World Congress of Dermatology, being held June 8-13, 2015, in Vancouver, Canada. The data will be pre... 
 Printer Friendly Version
05/28/15Dermira to Present at Jefferies 2015 Global Healthcare Conference
MENLO PARK, Calif., May 28, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced that it will present at the Jefferies 2015 Global Healthcare Conference. Tom Wiggans, chairman and chief executive officer of Dermira, is scheduled to present at 9:30 a.m. ET on Thursday, June 4, 2015 in New York. A live audio webcast and replay of the presentation w... 
 Printer Friendly Version
05/12/15Dermira Reports First Quarter 2015 Financial Results and Provides Corporate Update
Three Late-Stage Programs Continue to Progress MENLO PARK, Calif., May 12, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today reported financial results for the quarter ended March 31, 2015 and provided an update on its clinical development programs. "Dermira is currently focused on advancing its pipeline of late-stage dermatology product candidates... 
 Printer Friendly Version
04/09/15Dermira Doses First Patient in DRM01 Phase 2b Acne Trial
Study to Enroll Approximately 400 Patients With Moderate-to-Severe Acne Vulgaris MENLO PARK, Calif., April 9, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced the initial dosing of the first patient in a Phase 2b dose-ranging trial for DRM01 in patients with facial acne vulgaris. The randomized, multi-center, double-blind, parallel-group, ve... 
 Printer Friendly Version
04/08/15Dermira to Present at the 14th Annual Needham Healthcare Conference
MENLO PARK, Calif., April 8, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced that it will present at the 14th Annual Needham Healthcare Conference. Tom Wiggans, chairman and chief executive officer of Dermira, is scheduled to present at 10:40 a.m. ET on Wednesday, April 15, 2015 in New York. A live audio webcast and replay of the presentatio... 
 Printer Friendly Version
03/25/15Dermira Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Corporate Update
DRM01 Phase 2b Trial in Acne to Start April 2015 Conference Call Today at 4:30 p.m. Eastern Time MENLO PARK, Calif., March 25, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today reported financial results for the quarter and year ended December 31, 2014 and provided an update on its clinical development programs and outlook for 2015. The company ... 
 Printer Friendly Version
03/23/15Clinical Data for Dermira's DRM01 Acne Program Presented at Dermatology Meeting
Phase 2a Trial Met Primary Endpoints With Statistical Significance MENLO PARK, Calif., March 23, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced the presentation of clinical data from its successful DRM01 Phase 2a trial in patients with facial acne vulgaris. The primary endpoints in this trial, the changes from baseline in inflammatory and ... 
 Printer Friendly Version
03/18/15Dermira to Report Fourth Quarter and Full Year 2014 Financial Results
Management to Host Webcast and Conference Call on March 25, 2015 at 4:30 p.m. ET MENLO PARK, Calif., March 18, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated dermatology products to dermatologists and their patients, today announced that it will report fourth quarter and full year 2014 financial results after the close of U.S. financial markets on March 25, 2015. Dermira management will host a webcast... 
 Printer Friendly Version
03/12/15Dermira Announces Late-Breaking Oral Presentation on DRM01 in Acne at 2015 AAD Annual Meeting
Positive Results of Phase 2a Trial to be Presented on March 20, 2015 MENLO PARK, Calif., March 12, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced that clinical data from its DRM01 Phase 2a trial in acne will be presented at the Late-Breaking Research in Dermatology Forums during the American Academy of Dermatology (AAD) Annual Meeting bein... 
 Printer Friendly Version
02/05/15Dermira Announces Positive Phase 2b Results for DRM04 in Patients With Hyperhidrosis
Phase 3 Program Expected to Start in Second Half of 2015 MENLO PARK, Calif., Feb. 5, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced positive Phase 2b study results for DRM04, its proprietary topical anticholinergic product, in patients with axillary hyperhidrosis, or excessive underarm sweating. Based on the results of this study (DRM04-HH... 
 Printer Friendly Version
01/29/15Dermira to Present at the 2015 Leerink Global Healthcare Conference
MENLO PARK, Calif., Jan. 29, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced that it will present at the 2015 Leerink Global Healthcare Conference. Tom Wiggans, chairman and chief executive officer of Dermira, is scheduled to present at 2:15 p.m. ET on Thursday, February 12, 2015, at The Waldorf Astoria Hotel in New York. A live audio webcas... 
 Printer Friendly Version
01/08/15Dermira and UCB Announce Start of Phase 3 Program for CIMZIA(R) (certolizumab pegol) in Psoriasis
Phase 3 program aims to address patient need for alternative treatment options in moderate-to-severe psoriasis   Program includes the first Phase 3 study in psoriasis comparing two anti-TNFs   Based on current enrollment projections, top-line data from these studies are expected in 2017 MENLO PARK, Calif., and BRUSSELS, Belgium, Jan. 8, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc., a specialty biopharmaceutical company focused on bringing innovative and differentiated medic... 
 Printer Friendly Version
12/22/14Dermira Added to Russell 2000(R) Index
MENLO PARK, Calif., Dec. 22, 2014 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients, today announced that the company was added to the Russell 2000® Index as part of Russell Investments' quarterly addition of select initial public offering (IPO) companies. Dermira joined the index after the equity markets closed on December 19, 2014. The stock a... 
 Printer Friendly Version
11/12/14Dermira Reports Third Quarter 2014 Financial Results and Provides Corporate Update
REDWOOD CITY, Calif., Nov. 12, 2014 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients, today reported financial results for the quarter ended September 30, 2014. "With the clinical advancement of our three late-stage product candidates, the addition of key executives, and the successful completion of our initial public offering, 2014 has bee... 
 Printer Friendly Version
10/02/14Dermira Prices Initial Public Offering
REDWOOD CITY, Calif., Oct. 2, 2014 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients, today announced the pricing of its initial public offering of 7,812,500 shares of common stock at a price to the public of $16.00 per share. The shares are expected to begin trading on The NASDAQ Global Select Market on October 3, 2014 under the symbol DERM. In... 
 Printer Friendly Version
08/19/14 Dermira Completes $51 Million Financing and Expands Management Team and Board of Directors
REDWOOD CITY, CA – August 19, 2014 – Dermira, a specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients, today announced that it has completed a $51 million Series C financing. Existing investors Bay City Capital, New Enterprise Associates (NEA), Canaan Partners and UCB S.A. were joined by new investors Apple Tree Partners, Aisling Capital, Rock Springs Capital, Sabby Capital and other healthcare inve... 
Download PDFPrinter Friendly Version
07/03/14UCB and Dermira enter into strategic collaboration in dermatology to broaden patient access to Cimzia® (certolizumab pegol)
UCB and Dermira enter into strategic collaboration in dermatology to broaden patient access to Cimzia® (certolizumab pegol) Dermira obtains exclusive rights to develop Cimzia® in psoriasis in the US, Canada and the European Union Driven by positive Phase 2 results with Cimzia® in psoriasis and the Phase 3 results in psoriatic arthritis1,2 Subject to regulatory approval in psoriasis, Dermira is granted exclusive rights to market Cimzia® to dermatologists in the US and Canada   Bruss... 
Download PDFPrinter Friendly Version
01/12/14Dermira Announces Development and Corporate Progress
Five Ongoing Phase 2 Clinical Trials Targeting Acne, Psoriasis, Atopic Dermatitis, Rosacea and Hyperhidrosis REDWOOD CITY, CA – Dermira, a development-stage biotechnology company focused on developing innovative medical dermatology products for dermatologists and their patients, announces the progress of three programs into five Phase 2, proof of concept, clinical trials.  The programs include DRM01, a novel, sebum inhibitor for acne; DRM02, a unique PDE4 inhibitor for inflammatory skin ... 
Download PDFPrinter Friendly Version
06/11/13Dermira Raises $35M to Fund Innovation in Dermatology
Existing Investors Joined by Maruho, the Leading Dermatology Company in Japan REDWOOD CITY, CA – June 11, 2013 – Dermira, a development-stage biotechnology company focused on developing and commercializing innovative new therapies in dermatology, today announced that it has raised $35 million of new funding in a Series B financing and related transaction. In this round, new investor, Maruho Co., Ltd. (Maruho), the leading dermatology company in Japan, joins Dermira’s existing investors, Bay C... 
Download PDFPrinter Friendly Version
02/01/13A Win for Skin
Dermira aims $40M at clear target:  Acne BY RON LEUTY San Francisco Business Times Vol. 27, No. 28 February 1–7, 2013 Tom Wiggans and Gene Bauer are putting more skin in the game. The dynamic duo of dermatology drug companies — who led, built and sold Bay Area companies Peplin Inc. and Connetics Corp. — are at it again with Dermira Inc. The Redwood City company, which has lined up more than $40 million in venture funding, has one treatment in an early-stage clinical trial and two mor... 
Download PDFPrinter Friendly Version
10/20/11Dermira Announces a $42m Series A Financing to Fund Therapeutic Advances in Dermatology
October 20, 2011 – Dermira today announced a $42 million Series A financing to support the acquisition, development and commercialization of novel therapeutics in dermatology. The company was founded and seed financed in late 2010 by former members of the Peplin and Connetics leadership teams, including Tom Wiggans, who will serve as Chief Executive Officer, and Dr. Eugene Bauer, who will serve as Chief Medical Officer, together with Bay City Capital. They are joined by Chris Griffith, previousl... 
Download PDFPrinter Friendly Version